Loading stock data…
$0.85-0.01 (-1.30%)
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
Compass Therapeutics, Inc. in the Healthcare sector is trading at $0.85 with a market capitalization of $152M. Wall Street consensus targets $5.45 (11 analysts), implying a +544.8% move over the next 12 months. The stock is currently near its 52-week low of $0.82, remaining 75.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.98M↓ | -$20.30M↓ | -$17.99M↓ | -$15.82M↑ | -$21.07M |
| Net Income | -$25.15M↓ | -$18.32M↓ | -$15.72M↓ | -$14.26M↑ | -$19.88M |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bisp...